Gruticibart

Phase 2

OOHSU Knight Cancer Institute

Gruticibart is one of 4 therapeutic programs targeting Thrombosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ThrombosisRecruiting

ThrombosisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Thrombosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

5 2

VEOPOZ

Regeneron

Approved

1 3

Brilinta

AstraZeneca

Preclinical

2 4

Gruticibart

OOHSU Knight Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Thrombosis

NCT07498517

Clinical

Trials by Indication[1]

Thrombosis1 trial

A Study to Evaluate the Safety and Efficacy of a Single Dose of Gruticibart for the Prevention of Early Catheter-related Thrombosis

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT07498517·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gruticibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gruticibart. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — OHSU Knight Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: OOHSU Knight Cancer Institute

Gruticibart

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Thrombosis1 trial

References

Drug Info

Quick Facts

Related News